Moderna COVID-19 Shot Lowers Risk Of Infection, Hospitalization Compared To Pfizer's
Moderna COVID-19 Shot Lowers Risk Of Infection, Hospitalization Compared To Pfizer's
A new real-world study funded by the Department of Veterans Affairs (VA) showed that compared to those who received $Pfizer(PFE.US)$ COVID-19 vaccine, $Moderna(MRNA.US)$ vaccine recipients had a significantly lower risk of SARS-CoV-2 infection and related hospitalizations.
退伍軍人事務部(VA)資助的一項新的現實世界研究顯示，與那些接受$輝瑞(PFE.US)$新冠肺炎疫苗，$Moderna(MRNA.US)$接種疫苗的人感染SARS-CoV-2和相關住院的風險顯著降低。
Lower risk was observed across all age groups, comorbidity-burden categories, and race.
Authors of the study, published as a pre-print last week, noted differences between Moderna's mRNA-1273 vaccine and Pfizer's BNT162b2 "in risk of infection or hospitalization were progressively greater when the follow-up period was longer."
The study evaluated over 900,000 vaccine recipients, followed for a mean of 192 days, during which there were almost 17,000 infections, more than 3,500 hospitalizations, and 381 deaths.
While fewer patients who received Moderna's vaccine died than Pfizer (168 versus 213), the researchers said this difference was not statistically significant.
Price Action: PFE stock is up 0.17% at $56.32, MRNA stock is down 4.63% at $222.88 during the market session on the last check Tuesday.
在所有年齡組、共病負擔類別和種族中都觀察到較低的風險。
這項研究的作者上週發表了一份預印本，指出Moderna的mrna-1273mRNA-1273疫苗和輝瑞的bnt162b2之間的不同之處在於，“隨着隨訪期的延長，感染或住院的風險逐漸增大。”
這項研究評估了超過90萬名疫苗接受者，平均持續192天，在此期間有近1.7萬人感染，3500多人住院，381人死亡。
雖然接種Moderna疫苗的患者死亡人數比輝瑞少(168人比213人)，但研究人員表示，這一差異在統計學上並不顯著。
價格行動：週二尾盤，PFE股票上漲0.17%，至56.32美元，mRNA股票下跌4.63%，至222.88美元。